drugset
drugset / Trial / NCT04523285

A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics

NCT04523285 ↗

Phase 1 Unknown 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728 tablets in subjects with advanced solid tumor or hematologic tumor.

Timeline

Start
2020-10-26
Primary completion
2021-12-31
Completion
2022-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3728 Small molecule — Oral

Indications

No indication recorded.